Zynerba Pharmaceuticals Inc (ZYNE) stock is up 6.7% Wednesday and higher by 15% over the last week. ZYNE stock is up 63.11% over the last 30 days and has risen 49.47% over the last 12 months. The average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives ZYNE stock a score of 79 out of a possible 100.
That score is chiefly influenced by a long-term technical score of 100. ZYNE’s score also includes a short-term technical score of 93. The fundamental score for ZYNE is 44. In addition to the average rating from Wall Street analysts, ZYNE stock has a mean target price of $19.58. This means analysts expect the stock to climb 38.77% over the next 12 months.
What’s Happening with ZYNE Stock Today
Zynerba Pharmaceuticals Inc (ZYNE) stock is higher by 6.73% while the S&P 500 has risen 0.76% as of 3:03 PM on Wednesday, May 15. ZYNE has risen $0.89 from the previous closing price of $13.22 on volume of 1,989,020 shares. Over the past year the S&P 500 has gained 4.61% while ZYNE has risen 49.47%. ZYNE lost -$2.27 per share in the over the last 12 months.